Market Overview

The global Cell Banking Outsourcing Market in terms of revenue was estimated to be worth $ 12.29 Million in 2023 and is poised to reach $ 47.89 Million by 2032, growing at a CAGR of 16.31% from 2024 to 2032.

Outsourcing of cell banking is an important market that encompasses the third-party services and solutions given to store, manage, and preserve biological samples - mainly cells and tissues. The outsourcing of cell banking has become increasingly popular today due to the increased demands for bio banking, which is brought about by improved and enhanced biotechnology, regenerative medicine, and personalized medicine. As research institutes and biopharmaceutical companies look for ways to simplify their business processes while saving costs, outsourcing their cell banking services has also become a strategic decision for allowing them to maintain their key competencies by outsourcing that service to third-party specialist providers who are better qualified to perform those services.

Trend of development in cell-based therapeutic and vaccine-related products by the biopharmaceutical industry, over the past few years. This has increased the need for secure and efficient storage of cell lines, stem cells, among other biological materials. In cell banking, the organization will benefit from current advanced storage technologies, strict compliance to regulatory standards, optimized sample management systems. This will assure that the integrity and viability of biological samples are maintained over time; important for successful research and therapeutic applications.

The cell banking market offers different types of service provisions, like development of cell lines, freezing, quality control, inventory management, and more. The services are generally customized to meet the research organizations, academic institutions, pharmaceutical companies, and other concerned parties' needs, while the technological improvements-for example, in automated storage technologies and track mechanisms-have improved the efficiency and performance capability of cell banking operations.

North America dominates the cell banking outsourcing market due to the presence of a strong biopharmaceutical industry, extensive research, and a favourable regulatory climate. However, growth rates are being witnessed in Europe and Asia-Pacific due to increased investment in biotechnology and healthcare research as well as the rising number of bio banks.

The outsourcing market for cell banking plays a critical role in the biopharmaceutical and research industries that ensure safe and efficient handling of biological samples. An organization partnering with specialized service providers would be able to optimize their research capabilities and compliance to regulations, furthering their operational efficiency as they push forward healthcare and therapeutic development.

Key Findings

• In September 2021, DCGI approved a clinical trial for Life Cell's Mesocel, a therapy-derived MSC of umbilical cord tissue intended to treat patients with acute respiratory distress, COVID-19, and pneumonia.
• In May 2021, in order to develop cell therapies for the treatment of eye disorders, Opsis Therapeutics, FUJIFILM Cellular Dynamics, and Blue Rock Therapeutics engaged in strategic research and development.

Market Drivers

Rising Demand for Biologics and Cell-Based Therapies

Increased interest in biologics-from the level of monoclonal antibodies and cell therapies through to gene therapies, indeed calls for the use of accurate cell banking solutions. Generally, high advanced therapeutics call for complex handling and storage purposes for efficiency. Viability and functionality of cells will be compromised since slight alteration can result in degradation as it also impacts the study result and quality of the item in question.

The biopharmaceutical companies enjoy various benefits due to the outsourcing of cell banking services to the service providers specialized in that type of service. They do possess experience, infrastructure, and even advanced technologies required for preservation at optimal conditions of the cells. Their cryopreservation systems are at advanced standards, their automated storage solutions, and also, high quality control procedures assist in strict regulation requirements adherence.

Companies can focus more on their core competencies like research and development and less on biological material safety, management, and storage through collaboration with experienced cell banking providers. The collaboration also not only increases the operational efficiency but accelerates the pace of developing innovative therapies toward improved patient outcomes in the medicine field.

Key Findings

• The California-based bioengineering company ATUM unveiled its Good Manufacturing Practices (cGMP)-compliant Master Cell Banking production services in April 2022. This new feature enables ATUM to provide a complete cell line creation solution that supports IND applications, from DNA design to the release of Master Cell Banks (MCB) and Working Cell Banks (WCB).

Market Opportunities

Advancements in Personalized Medicine

A cell-based therapy would be expected based on this ever-evolving landscape in personalized medicine and these patient-specific requirements were on the rise. Tailoring individualized therapies through unique biological profiles on patient-specific factors, this primarily involves cell usage extracted directly from patients; thus, they must be handled delicately in relation to their storage and handling to sustain them for proper function or work in their intended medical context. Such cell banking services are growing relatively more beneficial within such parameters as it places responsibility in the hands of trained service providers and professionals to handle these biological resources responsibly within their infrastructure.

For Researchers and Clinicians who could store patient-derived cells within highly controlled conditions that support easy re-access for studies that build customized treatment, there should be a real hope from such researches as well as clinical trials when designed to find innovative remedies. This trend helps patients by turning out targeted, effective therapies, thereby enhancing the efficiency of personalized medicine while maintaining the regulatory compliance standards of healthcare organizations through the use of cell banking providers with their specialized knowledge and advanced technologies.

Market Restraining Factors

Regulatory Compliance Challenges

Strict regulatory frameworks developed by health authorities, including the FDA and EMA, govern cell banking. This ensures that biological materials like cell lines, tissues, and stem cells are safe, effective, and of quality. Compliance with such standards is essential to the maintenance of integrity in cell banking operations and to the guarantee that the materials held within the banks are safe for research and therapeutic applications.

Such a complex landscape is particularly challenging for outsourced providers, and the need for quality management systems, regular audits, and fully documented evidence of compliance adds to the cost. This demands significant investment in training and technology for improving infrastructure. Such non-compliance can lead to grave consequences, including monetary sanctions, loss of operating licenses, and even litigation. It is likely to deter the companies from outsourcing their cell banking needs. As a result, the fear of non-compliance and the related risk might make some companies select in-house solutions and may restrict the growth prospects of the outsourcing market in this area.

Segmentation Analysis

The market scope is segmented because of by Type of Cell Bank, by Application, by Service Type, by End-User.

By Type of Cell Bank

Based on the Type of Cell Bank of the market is segmented into Cell Line Banks, Primary Cell Banks, Stem Cell Banks.

Cell lines that are immortalized, primarily applied in research and bio production, account for the dominating cell line banks segment in the cell banking outsourcing market. For instance, HeLa cells have been very extensively applied in bio production and drug discovery and are extremely valuable in research, vaccine development, and toxicity testing as a sample of human cervical cancer cells. Alternatively, primary cell banks focus on storage of freshly isolated cells directly from biological sources with a high level of viability and functionality tailored for certain applications. For example, often peripheral blood mononuclear cells are stored in cell banks, as they closely resemble conditions in the human organism in immunology research and clinical trials. The last important role played by stem cell banks is to store pluripotent stem cells. These have the potential to differentiate into many cell types and, thus, form a vital part in the development of therapies aiming at repairing damaged tissues and organs. Hence, they become an essential part of novel medical treatments. All these segments underpin the divergent requirements within the cell banking industry, meeting research as well as therapeutic requirements.

By Application

Based on the Application of the market is segmented into Biopharmaceutical Development, Regenerative Medicine, Research and Development.

Out sourced cell banking has largely been dominated by biopharmaceutical development, because the companies continue to depend on the same for support of their biologics such as vaccines and monoclonal antibodies. For example, due to the COVID-19 pandemic, pharmaceutical companies were noted to be using outsourced cell banks to maintain the CHO (Chinese Hamster Ovary) cell lines to support the efficient production of therapeutic proteins and vaccines. In cell banking, the area that proves important is in the regenerative medicine area that is primarily involved in the development of therapies to replace or repair damaged tissues and organs. In this context, stem cell banks carry pluripotent stem cells which can differentiate into various types of cells to be applied in new treatments such as injuries in the spinal cord and heart disease. Academic and research centres make use of outsourcing services of cell banking in broad-scale studies in the area of cell biology, genetics, and oncology. Most of these institutions, based on their research topics, will need access to the rare cell lines and newly collected biological materials to understand how to find a cure and a therapy for diseases. As a whole, outsourcing services enhance efficiency in operations by availing high-quality materials, regardless of the specific use. It has enormously added value to the lives sciences through advancements.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America leads the market due to a strong biopharmaceutical industry, extensive research capabilities, and high spending in the life sciences. The top pharmaceutical companies and research centres of the United States and Canada boost demand for outsourced cell banking services in the region. Strict standards and regulations by the FDA and other agencies ensure that there are strict high-quality cell banking operations, hence contributing to the growth of the market.

The market for cell banking outsourcing in Europe is strong, led by a mix of established biopharmaceutical companies and a rapidly increasing number of biotech start-ups. Countries like Germany, France, and the UK lead the way, with these countries having friendly regulatory policies and research funding. The EMA clearly gives guidelines, thus promoting quality standards in cell banking, which makes the region a favourite for outsourcing services. Increased interaction between academia and industry in Europe increases the market with innovation and novel therapies.

The Asia-Pacific region is emerging fast as a significant player in the cell banking outsourcing market, which shows the fastest growth rates. Some growth factors are increased investment in biotechnology, increase of the healthcare infrastructure, and also a high demand for the production of biopharmaceuticals. Other areas such as China and India have a boom of this kind of development, brought about by an ever increasing population and a higher disposable income. Also, through these governments, there has been encouragement for research and innovations in life sciences.

The cell banking outsourcing markets of Latin America and Middle East & Africa are currently emerging and promising ones. Improving healthcare requirements as well as the demand for advanced solutions in therapy are driving countries to invest into biotechnological and pharmaceutical sectors. Research activities, undertaken by local governments along with international organizations, are promoting the potential of these industries and are thus providing scopes for further development of services in terms of cell banking outsourcing across these regions.

The cell banking outsourcing market is generally dynamic across regions, with North America and Europe leading at present, while Asia-Pacific is emerging as a promising growth frontier. Diverse needs and trends in these regions underscore the importance of tailored solutions and strategic partnerships to capitalize on the opportunities within the market.

List of Companies Profiled

• Bio Outsource (Sartorious)
• BSL Bioservice
• Cryo-Cell International, Inc
• Charles River Laboratories
• LifeCell
• GBI
• Lonza
• SGS Société Générale de Surveillance SA
• Perfectus Biomed Limited.

Key Industry Developments

• In May 2022, in order to make cord blood stem cell banking available to everyone, irrespective of ethnicity, socioeconomic background, or income, Anja Health secured USD 4.5 million in seed funding. The company's community, strategic expansion, and leadership team will all benefit from the extra cash.
• In April 2022, Accelerated Biosciences, a pioneer in regenerative medicine using proprietary human trophoblast stem cells (hTSCs), and Pluristyx, a biotechnology company specialising in cutting-edge therapeutic tools and services, have agreed to produce clinical grade hESC banks in accordance with GMP criteria (GMP).

Report Coverage

The report will cover the qualitative and quantitative data on the Global Cell Banking Outsourcing Market. The qualitative data includes latest trends, market player’s analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Cell Banking Outsourcing market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Cell Banking Outsourcing. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Cell Banking Outsourcing companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Cell Banking Outsourcing Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Cell Banking Outsourcing Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Cell Banking Outsourcing Market valued?
• Which region has the largest share in 2024 for the global Cell Banking Outsourcing Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Cell Banking Outsourcing Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: